• 1
    Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1: 443446.
  • 2
    Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275285.
  • 3
    Lenschow D, Zeng Y, Thistlethwaite J et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789792.
  • 4
    Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434438.
  • 5
    Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates [see comments]. Nat Med 1999; 5: 686693.
  • 6
    Kenyon NS, Chatzipetrou M, Masetti M et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999; 96: 81328137.
  • 7
    Suthanthiran M, Morris RE, Strom TB. Immunosuppressants. cellular and molecular mechanisms of action. Am J Kidney Dis 1996; 28: 159172.
  • 8
    Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000; 70: 415419.
  • 9
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302.
  • 10
    Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 13031307.
  • 11
    Hale DA, Gottschalk R, Maki T, Monaco AP. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation 1997; 64: 897900.
  • 12
    Bolling SF, Lin H, Wei RQ, Linsley P, Turka LA. The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. J Surg Res 1994; 57: 6064.
  • 13
    Perico N, Imberti O, Bontempelli M, Remuzzi G. Toward novel antirejection strategies. in vivo immunosuppressive properties of CTLA4Ig. Kidney Int 1995; 47: 241246.
  • 14
    Azuma H, Chandraker A, Nadeau K et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996; 93: 1243912444.
  • 15
    Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265270.
  • 16
    Ossevoort MA, Lorre K, Boon L et al. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J Immunother 1999; 22: 381389.
  • 17
    Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 20372044.
  • 18
    Durham MM, Bingaman AW, Adams AB et al. Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 14.
  • 19
    Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464469.
  • 20
    Adams AB, Durham MM, Kean L et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 11031111.
  • 21
    Shirasugi N, Adams AB, Durham MM et al. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 26772684.
  • 22
    Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 13871388.
  • 23
    Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1- phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569575.
  • 24
    Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection. CTLA-4- and IL-10- dependent immunoregulation of alloresponses. J Immunol 2002; 168: 10801086.
  • 25
    Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 16411646.
  • 26
    Jones TR, Ha J, Williams MA et al. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J Immunol 2002; 168: 11231130.
  • 27
    Dyson PJ, Knight AM, Fairchild S, Simpson E, Tomonari K. Genes encoding ligands for deletion of VB11 T cells cosegregate with mammary tumour virus genomes. Nature 1991; 349: 531349.
  • 28
    Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40L prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 87898794.
  • 29
    Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592600.
  • 30
    Van Maurik A, Herber M, Wood KJ, Jones ND. Cutting edge: CD4 (+) CD25 (+) alloantigen-specific immunoregulatory cells that can prevent CD8 (+) T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol 2002; 169: 54015404.
  • 31
    Taylor PA, Lees CJ, Wilson JM et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100: 34003407.
  • 32
    Blaha P, Bigenzahn S, Koporc Z et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2002.
  • 33
    Markees TG, Phillips NE, Gordon EJ et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4 (+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 24462455.